ANI Pharmaceuticals ANIP Increase Decrease Of Accrued Expenses Compensation And Others
Increase Decrease Of Accrued Expenses Compensation And Others at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers.
The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about ANI Pharmaceuticals's increase decrease of accrued expenses compensation and others.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ANI Pharmaceuticals's increase decrease of accrued expenses compensation and others?
- ANI Pharmaceuticals (ANIP) reported increase decrease of accrued expenses compensation and others of -$21M in Q1 2026.
- How has ANI Pharmaceuticals's increase decrease of accrued expenses compensation and others changed year-over-year?
- ANI Pharmaceuticals's increase decrease of accrued expenses compensation and others decreased by 23.0% year-over-year, from -$17.08M to -$21M.
- What is the long-term trend for ANI Pharmaceuticals's increase decrease of accrued expenses compensation and others?
- Over 2 years (2021 to 2024), ANI Pharmaceuticals's increase decrease of accrued expenses compensation and others has grown at a 51.8% compound annual growth rate (CAGR), from -$3.64M to $8.38M.
- What does increase decrease of accrued expenses compensation and others mean?
- Tracks the net change in liabilities related to employee compensation, benefits, and other accrued operational expenses. This metric captures the timing difference between the accrual of labor-related costs and the actual cash disbursement. It is a standard measure of short-term operational cash flow management.